Ignite Creation Date:
2025-12-24 @ 10:22 PM
Ignite Modification Date:
2026-05-15 @ 5:34 PM
Study NCT ID:
NCT04634435
Status:
COMPLETED
Last Update Posted:
2025-01-20
First Post:
2020-10-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
Sponsor:
Biohaven Pharmaceuticals, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Multiple Myeloma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Cell Therapy | View |
| None | CIML NK cell therapy | View |
| None | cytokine induced memory-like natural killer cell therapy | View |
| None | immunotherapy | View |
| None | antibody-dependent cell-mediated cytotoxicity | View |
| None | ADCC | View |
| None | CD38 positive | View |
| None | CD38+ | View |
| None | plasma cells | View |
| None | multiple myeloma | View |
| None | hematological malignancies | View |